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OBJECTIVE — To determine the time course of changes in glucagon and insulin secretion in
children with recently diagnosed type 1 diabetes.
RESEARCH DESIGN AND METHODS — Glucagon and C-peptide concentrations
were determined in response to standard mixed meals in 23 patients with type 1 diabetes aged
9.44.6years,beginningwithin6weeksofdiagnosis,andevery3monthsthereafterfor1year.
RESULTS — Glucagonsecretioninresponsetoaphysiologicstimulus(mixedmeal)increased
by 37% over 12 months, while C-peptide secretion declined by 45%. Fasting glucagon concen-
trations remained within the normal (nondiabetic) reference range.
CONCLUSIONS — Postprandial hyperglucagonemia worsens signiﬁcantly during the ﬁrst
year after diagnosis of type 1 diabetes and may represent a distinct therapeutic target. Fasting
glucagonvaluesmayunderestimatetheseverityofhyperglucagonemia.Theopposingdirections
of abnormal glucagon and C-peptide secretion over time support the link between dysregulated
glucagon secretion and declining -cell function.
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P
atients with diabetes frequently
have a deﬁcient glucagon response
to hypoglycemia and exhibit an in-
appropriatelyhighglucagonresponsetoa
meal. This dysregulation has been attrib-
uted in part to a lack of intraislet insulin,
but the exact pathophysiologic mecha-
nisms remain controversial (1). Glucagon
excess and its contribution to postpran-
dial hyperglycemia have become treat-
menttargets,especiallyintheﬁeldoftype
2 diabetes. In this study, we describe the
time course of development of abnormal
glucagon secretion paralleled by decreas-
ing insulin secretion in a cohort of re-
cently diagnosed patients with type 1
diabetes.
RESEARCH DESIGN AND
METHODS— Children with new-
onset type 1 diabetes were recruited for a
randomized, placebo-controlled trial of
low-dose oral interferon- for preserva-
tion of -cell function (the primary out-
come of which will be published in a
separate report). Patients had a mean age
of9.44.6years,wereenrolledwithin6
weeks of diagnosis, and were free of other
signiﬁcant illness (n  23, 30% female,
91% Caucasian). Study approval was ob-
tainedfromtheinstitutionalreviewboard
at the National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK)
attheNationalInstitutesofHealth(NIH).
Parents gave written informed consent
and minors gave written assent before
enrollment.
Mixed meal testing was performed at
screening and every 3 months thereafter.
Patients fasted after midnight before test-
ing. For subjects on insulin pumps, basal
rates were continued but morning bolus
injections were withheld. For patients on
multipledailyinjectionsofinsulin,morn-
ing doses were withheld. The meal con-
sisted of Boost High Protein, 7 ml/kg
(maximum 400 ml), ingested over 5 min.
Blood samples were drawn at 10, 0, 30,
60, 90, and 120 min.
Plasma glucagon concentrations were
determined using a radioimmunoassay at
Mayo Medical Laboratories. The normal
range in healthy individuals was 60
ng/l, with an interassay coefﬁcient of vari-
ation (CV) of 18% and an intra-assay CV
of 15%. C-peptide concentrations were
determined with a competitive chemilu-
minescence assay at the NIH Clinical
Center laboratory. The normal range in
healthy individuals was 0.3–1.3 nmol/l,
with an intra-assay CV of 3.4% (at 1.45
nmol/l) and inter-assay CVs of 7.7 and
8.3% at 0.37 and 1.98 nmol/l, respec-
tively. The lower limit of detection was
0.17 nmol/l.
Area under the curve (AUC) for glu-
cagon and C-peptide were calculated us-
ing the trapezoidal method. The mean of
values obtained at 10 and 0 min was
used as the baseline value. Net glucagon
and C-peptide secretion following the
mixed meal were expressed as AUC.
Statistical analyses were performed
using SAS version 9.1 (SAS Institute,
Cary, NC). Results were described using
frequency distributions, Pearson’s corre-
lation coefﬁcients, and repeated-
measures ANOVA using PROC MIXED
for testing change over time. Opposing
change(i.e.,positiveforglucagonvs.neg-
ative for C-peptide, or vice versa) was as-
sessed using a sign test based on the sign
of the product of the slopes over time for
glucagon and C-peptide. All tests were
two-sided,withstatisticalsigniﬁcancede-
ﬁned as P  0.05. Data are presented as
means  SEM.
RESULTS— There were no differ-
ences between treatment groups (inter-
feron vs. placebo) for glucagon or
C-peptide AUC; therefore, all 23 subjects
were combined for subsequent analyses.
Subjects showed an increase in glucagon
secretion following the mixed meal, with
peak glucagon levels at 30 min (Fig. 1A).
Glucagon AUC progressively increased
over the 12-month observation period
(P  0.0008), whereas C-peptide AUC
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vs. 45% decline in C-peptide AUC over
12 months). Of the 23 subjects, 18 (78%)
showed opposing changes in glucagon
andC-peptideAUCovertime(P0.01).
The percent rise in meal-stimulated
C-peptide [100  (peak  fasting)/
fasting] declined over time, from 147 
22% at month 0 to 85  12% at month
12. In contrast, the percent rise in meal-
stimulated glucagon increased over time,
from6312%atmonth0to829%at
month 12. Fasting glucagon rose from
40  3 ng/l at month 0 to 46  3 ng/l at
month 12. No signiﬁcant correlations
were found between glucagon AUC and
A1C, insulin dose, or insulin dose-
adjusted A1C (data not shown).
CONCLUSIONS — The phenome-
non of elevated glucagon in response to
oral glucose or mixed meal testing has
been described cross-sectionally in pa-
tients with type 1 and type 2 diabetes,
generally of several years duration (2–5).
More recently, Porksen et al. (6) reported
a 17% rise in post–mixed meal glucagon
(measured as a single value at 90 min)
from 1 to 12 months after diagnosis of
type 1 diabetes. In the present study, we
demonstrate a progressive, 37% rise in
meal-stimulated glucagon secretion over
12 months after diagnosis of type 1 dia-
betes, paralleled by a 45% decline in C-
peptide secretion. Fasting glucagon rose
only 15% over 12 months and remained
within the normal range of the assay, sug-
gesting that hyperglucagonemia may not
be recognized if only fasting blood sam-
ples are obtained.
As seen in previous studies (7,8), the
ability of -cells to secrete insulin in re-
sponsetoastimulusdeclinedovertimein
our patients with type 1 diabetes. In con-
trast, the ability of -cells to secrete glu-
cagon in response to a stimulus increased
over time. This suggests that -cell secre-
tory reserve is not diminished by the on-
going autoimmune process in type 1
diabetes. Although the pathophysiology
of glucagon excess during hyperglycemia
in type 1 diabetes is not well understood,
the opposing directions of abnormal glu-
cagon and C-peptide secretion over time
support the link between dysregulated
glucagon secretion and declining -cell
function.
These data represent the most de-
tailed time course to date of the progres-
sion of abnormal glucagon secretion in
type 1 diabetes. We did not observe a sig-
niﬁcant correlation between glucagon
AUC and A1C or insulin dose; however,
this may be related to small sample size.
Nevertheless, the timing and rapid pro-
gression shown here suggest that excess
glucagon secretion may represent a dis-
tinct therapeutic target early in the course
of type 1 diabetes.
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Figure 1—Glucagon secretion after a mixed meal (A) and glucagon and C-peptide AUC after a
mixed meal (B) during the ﬁrst year after diagnosis of type 1 diabetes. Data are means  SEM.
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